drugset / Trial / NCT07051031

COVID-19 Reactogenicity

NCT07051031

Phase 4 Active not recruiting 1000 enrolled Marcel Curlin
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.

Timeline

Start
2025-10-01
Primary completion
2026-06-14
Completion
2026-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Nuvaxovid Vaccine
Subject mNEXSPIKE Messenger RNA (mRNA)

Indications